Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1919 1
1923 1
1924 1
1925 2
1928 2
1945 2
1946 7
1947 12
1948 12
1949 9
1950 5
1951 14
1952 12
1953 20
1954 16
1955 13
1956 19
1957 9
1958 6
1959 13
1960 19
1961 20
1962 27
1963 29
1964 30
1965 48
1966 59
1967 92
1968 117
1969 114
1970 128
1971 157
1972 194
1973 236
1974 256
1975 951
1976 1087
1977 1097
1978 1208
1979 1411
1980 1613
1981 1871
1982 1984
1983 2634
1984 2894
1985 3318
1986 3696
1987 4258
1988 4674
1989 6075
1990 6610
1991 7557
1992 8359
1993 9529
1994 10786
1995 12249
1996 13758
1997 15111
1998 16971
1999 19120
2000 21974
2001 24359
2002 27214
2003 30935
2004 36172
2005 40414
2006 45872
2007 50463
2008 55926
2009 60578
2010 69652
2011 79167
2012 88153
2013 96377
2014 104773
2015 113246
2016 120131
2017 127243
2018 135304
2019 146093
2020 169125
2021 190045
2022 191962
2023 188595
2024 72406

Text availability

Article attribute

Article type

Publication date

Search Results

2,190,799 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 29211723
Page 1
Targeting mutations in cancer.
Waarts MR, Stonestrom AJ, Park YC, Levine RL. Waarts MR, et al. J Clin Invest. 2022 Apr 15;132(8):e154943. doi: 10.1172/JCI154943. J Clin Invest. 2022. PMID: 35426374 Free PMC article. Review.
Targeted therapies have come to play an increasingly important role in cancer therapy over the past two decades. ...Targeted therapy has dramatically transformed treatment outcomes and disease prognosis in some settings, whereas in other oncologic contexts, targe …
Targeted therapies have come to play an increasingly important role in cancer therapy over the past two decades. ...Targeted t …
Strategies for targeting undruggable targets.
Zhang G, Zhang J, Gao Y, Li Y, Li Y. Zhang G, et al. Expert Opin Drug Discov. 2022 Jan;17(1):55-69. doi: 10.1080/17460441.2021.1969359. Epub 2021 Aug 30. Expert Opin Drug Discov. 2022. PMID: 34455870 Review.
INTRODUCTION: Undruggable targets refer to clinically meaningful therapeutic targets that are 'difficult to drug' or 'yet to be drugged' via traditional approaches. ...EXPERT OPINION: Targeting the undruggable expands the scope of therapeutically reachable …
INTRODUCTION: Undruggable targets refer to clinically meaningful therapeutic targets that are 'difficult to drug' or 'yet to b …
Genome engineering with zinc-finger nucleases.
Carroll D. Carroll D. Genetics. 2011 Aug;188(4):773-82. doi: 10.1534/genetics.111.131433. Genetics. 2011. PMID: 21828278 Free PMC article. Review.
Zinc-finger nucleases (ZFNs) are targetable DNA cleavage reagents that have been adopted as gene-targeting tools. ZFN-induced double-strand breaks are subject to cellular DNA repair processes that lead to both targeted mutagenesis and targeted gene rep …
Zinc-finger nucleases (ZFNs) are targetable DNA cleavage reagents that have been adopted as gene-targeting tools. ZFN-induced …
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. Corre I, et al. Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976. Cells. 2020. PMID: 32326444 Free PMC article. Review.
Osteosarcomas are very heterogeneous tumors, both at the intra- and inter-tumor level, with no identified driver mutation. Consequently, efforts to improve treatments using targeted therapies have faced this lack of specific osteosarcoma targets. ...This review desc …
Osteosarcomas are very heterogeneous tumors, both at the intra- and inter-tumor level, with no identified driver mutation. Consequently, eff …
Synthetic Lethality in Cancer Therapeutics: The Next Generation.
Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Setton J, et al. Cancer Discov. 2021 Jul;11(7):1626-1635. doi: 10.1158/2159-8290.CD-20-1503. Epub 2021 Apr 1. Cancer Discov. 2021. PMID: 33795234 Free PMC article. Review.
Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a wide array of novel SL drug targets. Here, we review concepts and lessons emerging from first-generation trials aimed at testing SL …
Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a …
Chasing molecular glue degraders: screening approaches.
Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C. Domostegui A, et al. Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. doi: 10.1039/d2cs00197g. Chem Soc Rev. 2022. PMID: 35723413 Review.
In particular, molecular glue degraders are monovalent compounds that orchestrate interactions between a target protein and an E3 ubiquitin ligase, prompting the proteasomal degradation of the former. This and other pharmacological strategies of targeted protein deg …
In particular, molecular glue degraders are monovalent compounds that orchestrate interactions between a target protein and an E3 ubi …
Targeting thromboinflammation in antiphospholipid syndrome.
Salet DM, Bekkering S, Middeldorp S, van den Hoogen LL. Salet DM, et al. J Thromb Haemost. 2023 Apr;21(4):744-757. doi: 10.1016/j.jtha.2022.12.002. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696191 Free article. Review.
All of these may serve as future therapeutic targets. Neutrophils produce neutrophil extracellular traps in response to aPL, and this leads to thrombosis. ...This review discusses mechanisms underlying thromboinflammation in APS that present targetable therapeutic o …
All of these may serve as future therapeutic targets. Neutrophils produce neutrophil extracellular traps in response to aPL, and this …
Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA. Ashique S, et al. Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301. Curr Drug Deliv. 2021. PMID: 34151759 Review.
Drug targeting can be accomplished in a number of ways that include enzyme mediation, pH-dependent release, use of special vehicles, receptor targeting, among other mechanisms. ...Overall, the article should make an excellent read for the researchers in this area. N …
Drug targeting can be accomplished in a number of ways that include enzyme mediation, pH-dependent release, use of special vehicles, …
Electrophilic warheads in covalent drug discovery: an overview.
Péczka N, Orgován Z, Ábrányi-Balogh P, Keserű GM. Péczka N, et al. Expert Opin Drug Discov. 2022 Apr;17(4):413-422. doi: 10.1080/17460441.2022.2034783. Epub 2022 Feb 6. Expert Opin Drug Discov. 2022. PMID: 35129005 Review.
However, versatile, selective warheads are not available for all targetable amino acids, hence discovery of new warheads for these residues is needed. Broadening the toolbox of the warheads could result in novel inhibitors even for challenging targets developing wit …
However, versatile, selective warheads are not available for all targetable amino acids, hence discovery of new warheads for these re …
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
Lev S. Lev S. Biochem Soc Trans. 2020 Apr 29;48(2):657-665. doi: 10.1042/BST20191055. Biochem Soc Trans. 2020. PMID: 32311020 Review.
However, for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, there are no clinically approved targeted therapies, and thus, an urgent need to identify potent, highly effective therapeutic targets. ...Particularly, we focus on therapeutic …
However, for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, there are no clinically approved targeted the …
2,190,799 results
You have reached the last available page of results. Please see the User Guide for more information.